AC Immune (NASDAQ:ACIU) Stock Has Consensus Price Target of $7.50 According to Brokerages

Shares of AC Immune (NASDAQ:ACIU) have been given a consensus rating of “Moderate Buy” by the five analysts that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, three have issued a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among brokerages that have covered the stock in the last year is $7.50.

A number of analysts recently commented on the stock. BTIG Research restated a “buy” rating and issued a $8.00 price objective on shares of AC Immune in a research report on Wednesday, September 23rd. HC Wainwright reiterated a “buy” rating on shares of AC Immune in a report on Thursday, September 24th. Weiss Ratings reissued a “sell (e+)” rating on shares of AC Immune in a research note on Wednesday, August 5th. Finally, Zacks Research upgraded AC Immune from a “hold” rating to a “strong-buy” rating in a report on Tuesday.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in ACIU. AXQ Capital LP acquired a new position in shares of AC Immune during the 2nd quarter worth approximately $25,000. Dimensional Fund Advisors LP lifted its holdings in AC Immune by 82.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 390,165 shares of the company’s stock valued at $1,071,000 after purchasing an additional 176,701 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership boosted its position in AC Immune by 8.0% during the first quarter. Arrowstreet Capital Limited Partnership now owns 405,658 shares of the company’s stock worth $1,116,000 after purchasing an additional 30,035 shares during the period. 51.36% of the stock is currently owned by institutional investors.

AC Immune Stock Up 0.8%

Shares of NASDAQ ACIU opened at $2.62 on Thursday. AC Immune has a 52-week low of $2.10 and a 52-week high of $4.00. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.02 and a current ratio of 0.93. The stock has a market cap of $266.64 million, a P/E ratio of -4.85 and a beta of 1.60. The firm has a 50 day moving average price of $2.59 and a 200 day moving average price of $2.67.

AC Immune (NASDAQ:ACIU) last posted its earnings results on Thursday, August 6th. The company reported $0.03 earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.13. The company had revenue of $18.67 million for the quarter, compared to analyst estimates of $9.59 million. AC Immune had a negative net margin of 245.32% and a negative return on equity of 100.17%. Analysts expect that AC Immune will post -0.6 EPS for the current year.

About AC Immune

AC Immune SA (NASDAQ: ACIU) is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland. Founded in 2003, the company develops precision medicines and diagnostic products designed to prevent, diagnose and treat neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease and other conditions associated with misfolded proteins.

AC Immune’s research is based on its SupraAntigen and Morphomer technology platforms, which are intended to identify disease-related proteins and generate therapies or diagnostic tools that target them.